Biologix Hair Inc. Appoints Two-Component Mixing and Delivery Systems Expert Wilhelm A. Keller Director

Biologix Hair Inc. Appoints Two-Component Mixing and Delivery Systems Expert 
Wilhelm A. Keller Director 
TORONTO, ONTARIO -- (Marketwired) -- 05/08/13 -- Biologix Hair Inc.
(OTCBB:BLGX) (OTCQB:BLGX) has appointed William A. Keller to the
Company's Board of Directors. 
Wilhelm A. Keller is the founder and majority shareholder of Medmix
Systems AG, a privately held, internationally operating, Swiss
company formed in 2006. Medmix Systems is a globally recognized
pioneer that designs and produces two-component mixing and delivery
systems for medical applications such as tissue adhesives and bone
Previously, Mr. Keller founded and wholly owned Mixpac Systems, a
Swiss company providing two-component mixing and delivery devices for
world-renowned manufacturers of industrial adhesives and various
dental materials, holding over 50 patents in this field. After 35
years of successful operation, Mixpac Systems was sold to Sulzer AG,
a major Swiss corporation and global industry leader formed in 1834.
Sulzer Mixpac Systems was formed in 2007.  
Wilhelm Keller has an education in mechanical engineering. At age 22,
he immigrated to Canada where he worked in the field of metallurgy
for several years. After his return to Switzerland, he completed his
engineering education, obtaining a Bachelor of Science in Mechanical
Engineering from the Engineering College of Biel, Switzerland.
Wilhelm Keller resides near Lucerne, Switzerland. 
Ron Holland, Biologix Chairman and CEO, stated: "We welcome Wilhelm
Keller to Biologix Hair Inc. Given his decades of experience in
two-component mixing and delivery systems, and the many patents he
holds in this field, I am confident he will be a valuable addition to
the Biologix Board of Directors and we appreciate his willingness to
contribute to our efforts moving forward." 
About Biologix Hair Inc. and Biologix Hair Science Ltd. 
Biologix Hair Inc. (Biologix Hair), together with its wholly owned
biotechnology subsidiary, Biologix Hair Science Ltd. (TM) (BHS), is
focused on realizing the full market potential for its patent-pending
hair loss formula - Biologix Revive - and its demonstrated ability to
prevent and reverse the effects of alopecia, which plagues hundreds
of millions worldwide. 
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial
treatments of Biologix Revive were administered to 5,000-plus
patients in South America suffering with varying degrees of alopecia,
as well as people seeking preventive treatment. The participating
treatment clinicians subjectively observed and reported that
virtually 100% of preventive care clients continued to retain their
healthy hair and an estimated 80-85% of the males and 90-plus% of the
females treated for hair regeneration experienced significant
regrowth of their own natural hair. And among alopecia areata
patients, virtually total hair regrowth was observed in 100% of the
cases. To date, no negative side effects have been reported. 
BHS is currently focused on obtaining FDA approval for its
breakthrough hair loss prevention and regeneration therapy and has
initiated a research and development program with one of the world's
leading medical research universities, the Beijing Institute of
Technology (BIT). The R&D program, expected to take approximately
twelve months to complete, is an important final step before formal
clinical trials and the FDA approval process begins. 
Additionally, on May 11, 2012, Venable LLC, the Washington-based law
firm overseeing the worldwide IP and regulatory approval processes on
behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on
behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is
an international treaty, administered by the World Intellectual
Property Organization (WIPO), to which 144 countries have as of now
contracted, including Canada and the United States. 
Biologix management is determined to be in a ready position to
capitalize on the high-margin sales potential of the Biologix Hair
Therapy System(TM), if and when FDA and other major market approvals
are forthcoming. 
As BHS advances the regulatory approval process, Biologix Hair,
together with wholly owned subsidiary companies operated by BHS, are
rapidly developing a global distribution network of licensed
clinicians and medical practitioners seeking to become Certified
Biologix Hair Therapists(TM) and secure exclusive territorial
purchasing and treatment rights for the Biologix Hair Therapy
Biologix Hair has decided not to risk creating any potential
regulatory conflicts by offering treatment outside the United States
and other major high-product-margin markets until FDA approval has
been granted. Therefore, the Biologix Hair Therapy System(TM) is not
yet available other than to the 5,000+ patients who participated in
the pre-clinical-trials conducted in South America. 
To learn more about Clinician Licensing opportunities, Click Here or
call toll free +1 855.737.0333 or +1 647.344.5900. 
This announcement is not an offer to sell any Biologix Hair Inc.
("Biologix") securities. Offers for any given security are made only
through applicable offering circulars and related documents filed
with the SEC pursuant to the Securities Act of 1933 or the Securities
Exchange Act of 1934. Certain statements contained herein and
subsequent oral statements made by and on behalf of Biologix may
contain "forward-looking statements". Such forward-looking statements
are identified by words such as "intends," "anticipates," "believes,"
"expects" and "hopes" and includes, without limitation, the
development of treatment centers and approval from regulatory
authorities. Forward-looking statements express our expectations or
predictions of future events or results. They are not guarantees and
are subject to many risks and uncertainties. There are a number of
factors beyond our control that could cause actual events or results
to be significantly different from those described in the
forward-looking statements. Any or all of our forward-looking
statements in this report or in any other public statements we make
may turn out to be wrong. We undertake no obligation to publicly
update or review any forward-looking statements, whether as a result
of new information, future developments or otherwise. In Canada,
Europe and the United States, the Biologix treatment is not approved
for use by Health Canada, EMA or the FDA. The company makes no
representations that it will receive Health Canada, EMA or FDA
Biologix Hair Inc.
Corporate Communications
Toll Free: +1 855.292.8585
Phone: +1 647.494.8001
Press spacebar to pause and continue. Press esc to stop.